Overall, our study revealed that METTL3, acting as an oncogene, maintained SOX2 expression through an m⁶A-IGF2BP2-dependent mechanism in CRC cells, and indicated a potential biomarker panel for prognostic prediction in CRC.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: